A microplate binding assay for the somatostatin type-2 receptor (SSTR2)

Area of Science:

• Oncology
• Radiochemistry
• Molecular Biology

Background:

• Somatostatin type-2 receptors (SSTR2) are crucial in pancreatic cancer.
• Novel somatostatin analogues like OctreoScan are used for diagnosis and therapy.
• Existing radioligands for SSTR2 detection are susceptible to proteases in pancreatic cells.

Purpose of the Study:

• To develop a robust methodology for monitoring SSTR2 expression in pancreatic cancer cells.
• To overcome limitations of standard binding assays caused by radioligand degradation.
• To establish a high-throughput assay for studying SSTR2 regulation.

Main Methods:

• Preparation of a novel radioligand, [125I][Tyr3]-octreotide, designed for enhanced stability.
• Incubation of the radioligand with AR4-2J pancreatic cancer cell plasma membranes.
• Optimization of binding assay conditions in 96-well plates for high-throughput analysis.

Main Results:

• The novel [125I][Tyr3]-octreotide radioligand demonstrated significantly greater resistance to degradation by pancreatic cell proteases compared to commercial tracers.
• This increased stability correlated with effective binding to SSTR2.
• Protease inhibitors enhanced specific binding, suggesting they also protect SSTR2 integrity.

Conclusions:

• A stable and effective radioligand, [125I][Tyr3]-octreotide, was developed for SSTR2 detection in pancreatic cancer.
• The optimized binding assay is suitable for high-throughput screening and in vivo studies.
• This methodology facilitates research into SSTR2 expression regulation in pancreatic tumors.